Alnylam Pharmaceuticals, Inc. (ALNY) stock analysis
Healthcare · Biotechnology
From the 10-K filed 2026-02-12
Business type: Asset play
How it makes money
It earns revenue by selling RNAi therapeutics globally and receiving royalties from collaborators on partnered products.
It generates worldwide product revenues from commercialized RNAi medicines such as AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO, primarily across the U.S. and Europe. Total revenues reached $3,713,937 thousand in 2025, driven by strong growth in its TTR franchise and supported by collaboration revenues and royalties from products commercialized by partners like Novartis and Sanofi.
Earnings depend heavily on the sustained growth of product sales, the expansion of its clinical pipeline into new indications such as cardiomyopathy, and the receipt of milestone and royalty payments from strategic collaborations with major pharmaceutical companies.
What protects it: the moat
It relies on a portfolio of patents, licenses, and proprietary RNAi technology platforms to maintain its competitive position.
Management asserts that its competitive advantage rests on its pioneering work in ribonucleic acid interference and proprietary delivery approaches like GalNAc conjugates and lipid nanoparticles. It actively seeks patent protection for its discoveries and licenses patent rights from third-party owners to safeguard its therapeutic pipeline against competitors.
However, other companies may challenge its patent rights or assert competing intellectual property, requiring ongoing enforcement and substantial legal expenses to defend its market position.
What growth costs
It reinvests heavily in research and development and commercial infrastructure to advance clinical programs and expand global operations.
It incurs significant costs to progress late-stage and early-stage clinical programs, such as the Phase 3 TRITON-PN, TRITON-CM, and ZENITH trials initiated in 2025, as well as to acquire, file, and protect intellectual property rights. Under its Alnylam 2030 strategy, it aims to reinvest approximately 30% of its revenues in non-GAAP research and development.
In addition to internal research, it invests in building marketing, sales, market access, and distribution capabilities to support its commercial products globally.
What could damage it
An inability to sustain and grow product sales or maintain key third-party collaborations could severely impair its financial results.
If sales of key products like AMVUTTRA fail to meet expectations, or if collaborators materially amend, terminate, or fail to perform their obligations under existing agreements, revenue streams would decline. Because operating results depend heavily on continuous commercial adoption and successful clinical development, such setbacks would adversely impact profitability and the trading price of its common stock.
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.